Bayer AG (Leverkusen, Germany) announced the grand opening of its new 70,000 square foot expansion at its Myerstown, Pennsylvania, facility, following a $44 million investment in 2022. This state-of-the-art facility is a testament to Bayer’s commitment to providing trusted self-care solutions to consumers across North America. In 2023, work was completed on Bayer’s first Cell Therapy Launch Facility in Berkeley, California, further underlining commitment to the North American market.
The ribbon-cutting ceremony was attended by Bayer leaders, employees, elected officials, and members of the local community to commemorate this exciting moment for Bayer and Pennsylvania’s Lebanon County. Bayer’s Myerstown site has a rich history dating back over 75 years, and it has now grown to become the largest manufacturing site in Bayer’s Consumer Health network globally, producing brands such as Bayer® Aspirin, Aleve®, Claritin®, One A Day®, Alka-Seltzer Plus®, Midol®, and more.
The Aspirin production line at the new Myerstown facility. (Source: Bayer)
Bayer’s commitment to growth extends beyond infrastructure and technology; it is an investment in the future of health and wellness for consumers across North America and the people of Myerstown. Along with expanding its physical footprint, the company is dedicated to digitally upskilling its workforce to ensure that employees and the local community are equipped with the knowledge needed to navigate the modern manufacturing landscape. Bayer also plans to welcome local high school educators to tour its Myerstown facilities and operations to bring back information and insights to their school districts.
“We recognize that the key to sustainable growth lies in our people. That’s why we will enable our workforce with the skills needed to adapt to new technologies so they can excel in their careers,” said Divakar Amin, Vice President & Site Manager of Myerstown. “We are proud to contribute to the local economy and foster a vibrant workforce made up of many Myerstown locals. Together, we are building a brighter future for Bayer and the communities we serve.”
“Our commitment to credible science and consumer advocacy drives our mission Health for all, Hunger for none,” said Michael Sullivan, Senior Vice President of Product Supply for Bayer’s Consumer Health division in North America. “We are excited about the positive impact this investment will have as we are paving the way for a healthier future where everyone has access to the products that they need to support their well-being.”